Q3 2021 13F Holders as of 9/30/2021
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
45.2M
-
Number of holders
-
61
-
Total 13F shares, excl. options
-
18.8M
-
Shares change
-
+2.61M
-
Total reported value, excl. options
-
$505M
-
Value change
-
+$68.6M
-
Number of buys
-
42
-
Number of sells
-
-14
-
Price
-
$26.97
Significant Holders of 4D Molecular Therapeutics, Inc. - Common Stock, par value $0.0001 per share (FDMT) as of Q3 2021
65 filings reported holding FDMT - 4D Molecular Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q3 2021.
4D Molecular Therapeutics, Inc. - Common Stock, par value $0.0001 per share (FDMT) has 61 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 18.8M shares
of 45.2M outstanding shares and own 41.57% of the company stock.
Largest 10 shareholders include VIKING GLOBAL INVESTORS LP (3.94M shares), BVF INC/IL (2.01M shares), JANUS HENDERSON GROUP PLC (1.52M shares), BlackRock Inc. (1.44M shares), Casdin Capital, LLC (1.12M shares), Aquilo Capital Management, LLC (1.1M shares), FMR LLC (1.02M shares), ArrowMark Colorado Holdings LLC (1M shares), VANGUARD GROUP INC (946K shares), and Octagon Capital Advisors LP (831K shares).
This table shows the top 61 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.